Comparison of the bronchodilator effect of inhaled short- and long-acting β2-agonists in children with bronchial asthma a randomised trial

被引:8
|
作者
Verini, M [1 ]
Verrotti, A [1 ]
Greco, R [1 ]
Chiarelli, F [1 ]
机构
[1] Univ Chieti, Dept Paediat, Chieti, Italy
关键词
D O I
10.2165/00044011-199816010-00003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: This study compared the bronchodilator effects of Short-acting (salbutamol and procaterol) and long-acting (salmeterol and formoterol) beta(2)-agonists in children with bronchial asthma. Patients: Twenty-seven (Is male, 9 female) children with bronchial asthma were enrolled in the study. Drugs were administered randomly in the morning for 5 days as follows: 1 single dose of two short-acting beta(2)-agonists, salbutamol 200 mu g and procaterol 20 mu g, and two long-acting beta(2)-agonists salmeterol 50 mu g and formoterol 24 mu g, and placebo. Results: All beta(2)-agonists demonstrated a significantly higher bronchodilator effect than that observed with placebo. This effect appeared to be due to the forced expiratory flows. Formoterol produced a higher bronchodilator effect than salbutamol, and salmeterol showed a bronchodilator effect comparable with salbutamol at 30 minutes but higher than salbutamol after 3 hours. Conclusion: Our study confirmed the efficacy of the bronchodilator effects of the beta(2)-agonists. Salmeterol and formoterol, in particular, produced an improvement in respiratory function with a significant increase in forced expiratory flows in children with bronchial asthma.
引用
收藏
页码:19 / 24
页数:6
相关论文
共 50 条
  • [1] Comparison of the Bronchodilator Effect of Inhaled Short- and Long- Acting β2- Agonists in Children with Bronchial AsthmaA Randomised Trial
    Marcello Verini
    Alberto Verrotti
    Rita Greco
    Francesco Chiarelli
    Clinical Drug Investigation, 1998, 16 : 19 - 24
  • [2] Long-acting inhaled β2-agonists in asthma therapy
    Moore, RH
    Khan, A
    Dickey, BF
    CHEST, 1998, 113 (04) : 1095 - 1108
  • [3] Potential masking effect on dyspnoea perception by short- and long-acting β2-agonists in asthma
    van Schayck, CP
    Bij-Hofland, ID
    Cloosterman, SGM
    Folgering, HTM
    van der Elshout, FJJ
    Van Weel, C
    EUROPEAN RESPIRATORY JOURNAL, 2002, 19 (02) : 240 - 245
  • [4] Effect of short- and long-acting inhaled beta 2-agonists on exhaled nitric oxide in asthmatic patients
    Yates, DH
    Kharitonov, SA
    Barnes, PJ
    EUROPEAN RESPIRATORY JOURNAL, 1997, 10 (07) : 1483 - 1488
  • [5] Comparison of bronchodilatory properties of transdermal and inhaled long-acting β2-agonists
    Yamagata, T.
    Hirano, T.
    Sugiura, H.
    Yanagisawa, S.
    Ichikawa, T.
    Ueshima, K.
    Akamatsu, K.
    Nakanishi, M.
    Matsunaga, K.
    Minakata, Y.
    Ichinose, M.
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2008, 21 (01) : 160 - 165
  • [6] Safety of long-acting β2-agonists in asthma
    de Benedictis, Fernando Maria
    Carloni, Ines
    THORAX, 2012, 67 (11) : 1014 - U110
  • [7] Safety of long-acting β2-agonists in asthma
    Rishton, Louise
    LANCET RESPIRATORY MEDICINE, 2016, 4 (11): : 860 - 860
  • [8] Inhaled corticosteroids plus long-acting β2-agonists as a combined therapy in asthma
    García-Marcos, L
    Schuster, A
    Barroso, NC
    EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (01) : 23 - 39
  • [9] Long-acting inhaled β2-agonists for stable COPD
    Dougherty, JA
    Didur, BL
    Aboussouan, LS
    ANNALS OF PHARMACOTHERAPY, 2003, 37 (09) : 1247 - 1255
  • [10] Long-acting β2-agonists in asthma:: safety concerns
    Wooltorton, E
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2005, 173 (09) : 1030 - 1031